XM does not provide services to residents of the United States of America.
G
G

GSK


News

Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply

UPDATE 2-Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply Adds new sourcing in paragraph 1, adds details throughout Oct 4 (Reuters) - GSK GSK.L , Sanofi SASY.PA and CSL Ltd CSL.AX have secured $72 million from the U.S. government to ramp up production of bird flu vaccines, a health official said on Friday during a press briefing . The move comes as a multi-state outbreak among livestock and poultry has caused human illnesses and infected more than 254 herds in 14 states since March,
G
S

Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply, Bloomberg News reports

Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply, Bloomberg News reports Oct 4 (Reuters) - GSK GSK.L , Sanofi SASY.PA and CSL Ltd CSL.AX have secured $72 million from the U.S. government to ramp up production of bird flu vaccines, Bloomberg News reported on Friday. Reporting by Sriparna Roy in Bengaluru; Editing by Shreya Biswas
G
S

Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply- Bloomberg News

MEDIA-Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply- Bloomberg News -- Source link: https://tinyurl.com/4px3r67d -- Note: Reuters has not verified this story and does not vouch for its accuracy
G
S

AstraZeneca, Danske Bank, Johnson Matthey

EUROPE RESEARCH ROUNDUP-AstraZeneca, Danske Bank, Johnson Matthey Oct 3 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including AstraZeneca, Danske Bank and Johnson Matthey, on Thursday. HIGHLIGHTS * AstraZeneca AZN.L : Jefferies cuts target price to 11,400p from 11,700p * Baltic Classifieds Group Plc BCG.L : Berenberg raises target price to 360p from 300p * Danske Bank DANSKE.CO : JP Morgan cuts target price to DKK 185 from DKK 190 * John
A
B
D
G
K
N
P
P
R
R
S
S
T
V
V
J
N
P

WHO recommends maternal vaccine and antibody shot to prevent RSV in infants

UPDATE 1-WHO recommends maternal vaccine and antibody shot to prevent RSV in infants Adds comments from WHO press conference in paragraphs 7 to 10 By Kashish Tandon and Bhanvi Satija Oct 1 (Reuters) - The World Health Organization on Tuesday recommended vaccinating pregnant women and administering infants with an antibody to prevent severe respiratory synctial virus (RSV) infection in newborns.
A
G
P
S

WHO recommends maternal shot and antibody therapy to prevent RSV in infants

WHO recommends maternal shot and antibody therapy to prevent RSV in infants Oct 1 (Reuters) - The World Health Organization on Tuesday recommended maternal vaccination and the use of an antibody therapy to prevent respiratory synctial virus (RSV) in infants. The recommendations, to administer both the shot and the antibody or either, come after the WHO's strategic advisory group on immunization met last week.
A
G
P
S

ASM International, Burberry, LVMH

EUROPE RESEARCH ROUNDUP-ASM International, Burberry, LVMH Oct 1 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including ASM International, Burberry and LVMH on Tuesday. HIGHLIGHTS * ASM International ASMI.AS : Stifel cuts target price to EUR 740 from EUR 800 * Burberry Group BRBY.L : HSBC raises target price to 770p from 690p * Carlsberg CARLb.CO : Jefferies cuts target price to DKK 1,000 from DKK 1,100 * LVMH LVMH.PA : HSBC raises target p
A
A
A
A
A
B
B
G
G
G
H
H
H
H
K
K
L
L
M
P
P
R
S
V
A
B
B
I

Pfizer to sell about $3.25 bln stake in Sensodyne-maker Haleon, bookrunner says

UPDATE 3-Drug giant Pfizer sells $3.3 bln stake in Sensodyne-maker Haleon Placing at a 3.3% discount to Haleon's last close Haleon to buy back 230 mln stg worth of shares from Pfizer Pfizer to remain top Haleon shareholder -LSEG data Updates dateline to Oct. 1, recasts with final pricing, shares, other details throughout By Shanima A Oct 1 (Reuters) - Pfizer PFE.N sold a stake in British consumer healthcare group Haleon HLN.L worth about $3.26 billion on Monday, cutting its shareholding in the m
G
G
P

Sensodyne maker Haleon to raise stake in China JV

UPDATE 2-Sensodyne maker Haleon to raise stake in China JV To buy additional 33% stake for $637 mln Will have option to buy out remaining 12% stake Deal 'strategically and commercially' compelling -CEO Recasts, adds detail, background By Yadarisa Shabong Sept 27 (Reuters) - Haleon HLN.L plans to increase its stake in its Chinese joint venture to 88% from 55%, the British consumer healthcare company said on Friday.
A
G

GSK Gets Positive EU Opinion For Liquid Menveo Vaccine

BRIEF-GSK Gets Positive EU Opinion For Liquid Menveo Vaccine Sept 24 (Reuters) - GSK plc GSK.L : POSITIVE EU OPINION FOR GSK LIQUID MENVEO VACCINE MARKETING AUTHORISATION IN EU EXPECTED BY NOVEMBER 2024 Source text for Eikon: ID:nRSX2993Fa Further company coverage: GSK.L
G

Biogen-UCB's lupus drug meets main goal of late-stage trial

CORRECTED-Biogen-UCB's lupus drug meets main goal of late-stage trial Corrects executive's name to Meyers from Myers in paragraphs 5 and 6 By Manas Mishra Sept 24 (Reuters) - Biogen BIIB.O and Belgian partner UCB UCB.BR said on Tuesday their experimental lupus treatment met the main goal of a late-stage trial in patients with the chronic disease, a surprise result after the drug failed an earlier mid-stage study.
A
B
G
U

US FDA approves AstraZeneca's self-administered nasal spray flu vaccine

UPDATE 2-US FDA approves AstraZeneca's self-administered nasal spray flu vaccine Reworks lede, adds details on availability in paragraphs 4, details on the vaccine in paragraph 5, other vaccines in paragraph 9 Sept 20 (Reuters) - The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's AZN.L nasal spray flu vaccine for self-administration, making it the first of its kind.
A
G
S

Coca-Cola plans to invest $1 billion in Nigeria operations, presidency says

Coca-Cola plans to invest $1 billion in Nigeria operations, presidency says ABUJA, Sept 19 (Reuters) - Coca-Cola plans to invest $1 billion in its Nigeria operations over the next five years, the country's presidency said after a meeting between President Bola Tinubu and senior executives of the soft drinks maker on Thursday. Tinubu met John Murphy, president and chief financial officer of Coca‑Cola KO.N , Zoran Bogdanovic, CEO of Coca-Cola HBC CCH.L - one of Coca-Cola's many bottlers worldwid
B
G
C

Boehringer Ingelheim faces second hung jury in Chicago Zantac trial

UPDATE 1-Boehringer Ingelheim faces second hung jury in Chicago Zantac trial Hung jury in latest Zantac cancer trial in Chicago Boehringer Ingelheim only defendant after settlements with GSK, Pfizer FDA pulled Zantac in 2020 over NDMA carcinogen concerns Updates Sept 18 story with statement from Boehringer Ingelheim in paragraph 5 By Brendan Pierson Sept 18 (Reuters) - The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, as j
G
P
S

Boehringer Ingelheim faces second hung jury in Chicago Zantac trial

UPDATE 1-Boehringer Ingelheim faces second hung jury in Chicago Zantac trial Hung jury in latest Zantac cancer trial in Chicago Boehringer Ingelheim only defendant after settlements with GSK, Pfizer FDA pulled Zantac in 2020 over NDMA carcinogen concerns Updates Sept 18 story with statement from Boehringer Ingelheim in paragraph 5 By Brendan Pierson Sept 18 (Reuters) - The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, as j
G
P
S

A second Zantac cancer trial ends with hung jury

A second Zantac cancer trial ends with hung jury Hung jury in latest Zantac cancer trial in Chicago Boehringer Ingelheim only defendant after settlements with GSK, Pfizer FDA pulled Zantac in 2020 over NDMA carcinogen concerns By Brendan Pierson Sept 18 (Reuters) - The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, as jurors in Chicago were unable to agree on whether Boehringer Ingelheim must pay damages to an Illinois man
G
P
S

GSK settles two California lawsuits related to heartburn drug Zantac

UPDATE 1-GSK settles two California lawsuits related to heartburn drug Zantac Adds background and context Sept 18 (Reuters) - British drugmaker GSK GSK.L said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued heartburn drug Zantac caused cancer. GSK does not admit to any liability in either settlement, it said in a statement.
G
P
S

GSK's RSV, Shingles vaccines show on-par immune response in joint trial

UPDATE 1-GSK's RSV, Shingles vaccines show on-par immune response in joint trial Adds details on study in paragraph 2, company's statement in paragraph 4 Sept 18 (Reuters) - British drugmaker GSK GSK.L said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.
G

GSK's RSV vaccine meets main goal when co-administered with shingles shot

GSK's RSV vaccine meets main goal when co-administered with shingles shot Sept 18 (Reuters) - British drugmaker GSK GSK.L said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles shot, met the main goal of a late-stage trial in adults over 50 years of age. The company said co-administration of the vaccines generated an immune response that was at least on-par with separate administration.
G

Gsk Says Japan Accepts NDA For Blenrep In Multiple Myeloma

BRIEF-Gsk Says Japan Accepts NDA For Blenrep In Multiple Myeloma Sept 17 (Reuters) - GSK plc GSK.L : GSK PLC - JAPAN FILING ACCEPTANCE: BLENREP MULTIPLE MYELOMA Source text for Eikon: ID:nRSQ4071Ea Further company coverage: GSK.L
G



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.